Artiva Biotherapeutics is a clinical-stage biotechnology enterprise dedicated to developing effective, safe, and accessible off-the-shelf allogeneic natural killer (NK) cell therapies. Its proprietary platforms focus on treating severe, B-cell-driven autoimmune diseases and oncology indications by combining specialized cellular immunotherapy candidates with monoclonal antibodies.
Executive compensation packages for Magna International's Chief Executive Officer, Swamy Kotagiri, consist of a mix of base salary, performance-based short-term cash bonuses, and long-term equity-incentive awards tied directly to multi-year financial targets, total shareholder return metrics, and strategic corporate milestones. Specific annual compensation figures are detailed transparently in the company’s annual proxy circulars filed with regulatory authorities.